Dr. Monte Jones

Hematology
5236 W University Dr, Suite 1000, 
Mckinney, TX 
Offers Telehealth
5236 W University Dr, Suite 1000, 
Mckinney, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Monte Jones is a Hematologist in Mckinney, Texas. Dr. Jones is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Follicular Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms (MPN), and Essential Thrombocythemia.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in TX
Hospital Affiliations
Baylor Scott And White Medical Center Mckinney
Medical Center Of Mckinney
Baylor Scott & White Medical Center - Centennial
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

TEXAS ONCOLOGY PA
5236 W University Dr, Suite 1000, Mckinney, TX 75071

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
postMONARCH: A Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib Plus Fulvestrant to Placebo Plus Fulvestrant in Participants With HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
Breast Cancer Index (BCI) Registry
Breast Cancer Index (BCI) Registry
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Diagnostic test
A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients With Surgically Resectable Non-Small Cell Lung Cancer
A Two-cohort, Phase 2 Study of FL-101 as Neoadjuvant Therapy in Patients With Surgically Resectable Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: January 11, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Enrollment Status: Terminated
Publish Date: September 11, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials
Similar Doctors
Distinguished in Familial Wilms Tumor 2
Dr. James B. Brugarolas
Hematology Oncology | Hematology | Oncology
Distinguished in Familial Wilms Tumor 2
Dr. James B. Brugarolas
Hematology Oncology | Hematology | Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (29.2 miles away)
214-645-0624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Brugarolas is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Dr. Brugarolas is rated as an Elite provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, Nephrectomy, and Thrombectomy.

Advanced in Familial Wilms Tumor 2
Dr. Jue Wang
Oncology | Hematology Oncology | Hematology
Advanced in Familial Wilms Tumor 2
Dr. Jue Wang
Oncology | Hematology Oncology | Hematology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (29.2 miles away)
214-648-7740
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jue Wang is an Oncologist and a Hematologist Oncology provider in Dallas, Texas. Dr. Wang is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Wilms Tumor, and WT1-Related Wilms Tumor Syndromes.

Advanced in Familial Wilms Tumor 2
Dr. Mary U. Milam
Hematology Oncology | Oncology | Hematology
Advanced in Familial Wilms Tumor 2
Dr. Mary U. Milam
Hematology Oncology | Oncology | Hematology
1307 8th Ave, Suite 205, 
Fort Worth, TX 
 (51.2 miles away)
817-924-4300
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mary Milam is a Hematologist Oncology specialist and an Oncologist in Fort Worth, Texas. Dr. Milam is rated as an Advanced provider by MediFind in the treatment of Familial Wilms Tumor 2. Her top areas of expertise are Pleuropulmonary Blastoma, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bone Marrow Aspiration, and Ureteroscopy. Dr. Milam is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jones's expertise for a condition
ConditionClose
      View All 34 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile